News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Colorado-Based GlobeImmune, Inc. Gives IPO A Second Shot, Aims For $35 Million


3/18/2014 7:36:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Maybe the second time will be the charm for GlobeImmune, a Louisville, CO-based biotech that filed for an IPO on Monday after seeing its first effort to do so come up empty. The company, which initially filed for an IPO in 2012 but cancelled those plans last October after it couldn’t find buyers, is looking to raise $35 million through a new offering—less than half the roughly $75 million sum it attempted to raise the first time around, according to its prospectus. GlobeImmune was founded in 1995 and is developing potential cancer and infectious disease treatments that are designed to work by stimulating T cells to seek out and attack certain specific, infected cells.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy
Read at Daily Camera
Read at Renaissance Capital
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES